Rockville, MD, - Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets, today announced that it has launched the BioFlash Biological Aerosol Collection, Detection andentification System.  The proprietary BioFlash Biological Detector is rugged, portable, and incorporates a high-volume aerosol sampler.  The well-integrated technology provides rapid, specific and sensitive detection of 21 biological threat agents in single test or multi-test formats within minutes.  BioFlash can be implemented in various scenarios including military force protection, facility security management, as well as field detection/identification and environmental monitoring. "BioFlash is the only system that has integrated the combination of collection, detection andentification facets and which can be further integrated for building security purposes or alternatively used in the field by our military and first responders or for environmental monitoring of pathogens," said Joe Hernandez, President and CEO of IBI. "We are proud to provide a complete stand-alone solution with such excellent performance which is low-risk, cost-effective and provides high-value information." "We are very excited about the performance validation testing at private and Government laboratories that BioFlash will be undergoing," said Richard Thomas, IBI's Vice President of Business Development.  "We will continue to expand the utilization capabilities of BioFlash with testing in a variety of environments and conditions." About Innovative Biosensors, Inc.  Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics.  IBI's technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications.  Additionally, the technology platform is being used to develop rapid tests for the detection of hospital-acquired infections. Additional information is available at www.innovativebiosensors.com. Contact:  Joe Hernandez, President and CEO Innovative Biosensors, Inc. Phone: (301) 517.0324                              Richard Thomas, Vice President of Business Development Innovative Biosensors, Inc. Phone: (410) 638.1144 This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors, Inc.'s mission to develop and commercialize instrument systems, Innovative Biosensors, Inc.'s ability to develop new technologies to conduct rapid diagnosis.  Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Innovative Biosensors, Inc. cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors, Inc.'s expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors, Inc.'s reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors, Inc.'s products, processes and technologies, Innovative Biosensors, Inc.'s ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.